Heung-Moon Chang

机构：Ulsan College, Asan Medical Center, University of Ulsan

发表论文 115 篇 · 总被引 3094 次 · h-index 30

代表论文

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study (2023 · The Lancet Oncology · 被引 282)
• Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. (2022 · Journal of Clinical Oncology · 被引 54)
• Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements (2021 · Cancer Research · 被引 35)
• Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. (2024 · Journal of Clinical Oncology · 被引 21)
• Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer (2025 · JAMA Oncology · 被引 11)
• Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX (2023 · Cancer Research and Treatment · 被引 10)